Tagged: oncology
30 results
Amwise Diagnostic PTE. LTD.
Amwise Diagnostic is a Singapore- and Taipei-based cancer genomics company behind RecurIndex, a multi-gene test built specifically on the genomes of Asian breast cancer patients. It reads a tumor's genetic profile alongside clinical factors to estimate the five-year risk of local recurrence and distant metastasis, helping physicians and patients decide whether chemotherapy or radiotherapy is actually needed - and helping many avoid treatment they don't.
Sabah Oney
Sabah Oney is the president and CEO of Dispatch Bio, a Philadelphia- and San Francisco-based biotech engineering a universal treatment for solid tumors using CAR-T cell therapy. Born in Cyprus and in the U.S. since age 18, he holds a genetics degree from the University of Kansas, a PhD in genetics and genomics from Duke, and an MBA from Stanford. Across nearly two decades in biotech he helped scale Ariosa Diagnostics (acquired by Roche), took Alector public as its chief business officer, co-founded Vilya, and served as a venture partner at ARCH. Dispatch launched publicly in 2025 with $216 million behind its FLARE platform and CAR-T pioneer Carl June among its founders.
Serge Messerlian
Serge Messerlian is the Chairman and CEO of Creyon Bio, a San Diego biotech using AI to design oligonucleotide medicines. A life-science operator with more than 25 years across oncology, hematology, immunology and rare disease, he has led Teon Therapeutics as CEO, run Janssen Oncology as President at Johnson & Johnson, and held senior roles at Actelion, Baxalta and Baxter International. He joined Creyon first as an investor and board member through DCVC Bio, then stepped in as Executive Chairman and Acting CEO in fall 2024 and took the full CEO title in April 2025 as the company prepares to enter the clinic in 2026.
Sofie Qiao
Sofie Qiao, Ph.D. is a chemist-turned-biotech-founder who has built a career at the intersection of hard science and dealmaking. Trained in organic chemistry at Harvard and MIT, she founded LEAD Therapeutics (acquired by BioMarin in 2010, source of the PARP inhibitor Talazoparib now sold by Pfizer), ran WuXi Ventures, and then founded and led Vivace Therapeutics from 2015 to 2026, raising more than $100 million to advance first-in-class small molecules targeting the Hippo/YAP-TEAD pathway in cancer. She now leads Virtuoso Therapeutics, another company she founded.
Steven Everett
Steven Everett is a biotechnology executive and cancer scientist who founded MaveriX Oncology in Palo Alto, California, where he serves as President and CEO. With a background rooted in more than two decades of cancer research at the University of Oxford, University of Dundee and UCSF, he has built his career around a single idea: making cancer drugs that switch on only inside tumors. At MaveriX he is developing conditionally activated small-molecule therapeutics that exploit hydroxylase biology in the tumor immune microenvironment, aiming to hit cancer hard while sparing healthy tissue.
Bryan Stuart
Bryan Stuart is the Chief Executive Officer and a director of Atavistik Bio, a Cambridge, Massachusetts biotechnology company building precision allosteric small molecule therapeutics on its Atavistik Metabolite-Protein Screening (AMPS) platform. He joined in July 2023 after more than two decades leading biopharma companies, including roles as CEO of Fulcrum Therapeutics, Yarra Therapeutics, and Kastle Therapeutics. Under his leadership Atavistik has raised a $120 million Series B in December 2025, later extended to $160 million, to advance its lead programs for hereditary hemorrhagic telangiectasia and myeloproliferative neoplasms toward the clinic.
Daniel Getts
Daniel Getts, PhD, is the co-founder and CEO of CREATE Medicines (formerly Myeloid Therapeutics), a Cambridge, Massachusetts biotech building RNA-based in vivo immune programming therapies that reprogram T cells, NK cells and myeloid cells directly inside the body. An immunologist trained at the University of Sydney with an MBA from Western Michigan, he previously founded Cour Pharmaceuticals and served as VP of Research at TCR2 Therapeutics. He has more than 45 peer-reviewed publications, multiple issued patents, and a track record of large pharma partnerships, including Takeda's $420M licensing deal for TIMP-GLIA. In May 2026 CREATE closed a $122 million Series B to advance its in vivo CAR pipeline across autoimmune disease and oncology.
Actithera
Actithera is a radiopharmaceutical biotech developing next-generation radioligand therapies (RLTs) for cancer. Founded in 2021 by medicinal chemist Andreas Goutopoulos and based in Cambridge, Massachusetts and Oslo, Norway, the company uses a proprietary, chemistry-led platform to design covalent small-molecule radioligands that lodge inside tumors, deliver targeted radiation, and clear quickly from healthy tissue. Its isotope-agnostic approach is engineered to match the residence time of a drug in a tumor to the half-life of long-lived radionuclides, with a lead program targeting Fibroblast Activation Protein (FAP). Actithera raised an oversubscribed $75.5M Series A in July 2025.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Ankyra Therapeutics
Ankyra Therapeutics is a clinical-stage Boston biotech developing anchored immunotherapy - a platform that physically tethers potent immune-modulating drugs to aluminum hydroxide so they stay concentrated inside a tumor rather than spreading through the body. Its lead candidate, tolododekin alfa (ANK-101), anchors the powerful cytokine IL-12 in the tumor microenvironment, aiming to unlock IL-12's anti-tumor activity while avoiding the systemic toxicity that has historically limited it. Founded in 2019 out of MIT science and led by CEO Howard L. Kaufman, the company is running Phase 1/1b trials in advanced solid tumors, including combinations with immune checkpoint inhibitors.
Antares Therapeutics
Antares Therapeutics is a Boston-based biotechnology company that discovers small-molecule precision medicines against historically 'undruggable' targets in cancer and other serious diseases. Spun out of Scorpion Therapeutics in June 2025 with $177 million in Series A financing, Antares combines proprietary compound libraries, next-generation mass spectrometry, chemical proteomics, and machine-learning-driven computational chemistry to find new binding pockets on proteins - such as transcription factors - that were long considered impossible to drug. Its lead program is slated to enter the clinic in 2026, and the company signed a collaboration worth up to $1.9 billion with Novartis in mid-2026.
Atavistik Bio
Atavistik Bio is a Cambridge, Massachusetts clinical-stage biotechnology company that discovers precision allosteric small-molecule medicines. Its proprietary AMPS (Atavistik Metabolite-Protein Screening) platform, paired with an AI-enabled discovery engine, uses natural metabolites as bait to reveal hidden allosteric pockets on disease-driving proteins that conventional drug discovery cannot reach. The company is advancing an oral AKT1-selective inhibitor for hereditary hemorrhagic telangiectasia (HHT) and a JAK2 V617F mutant-selective program for myeloproliferative neoplasms (MPNs).
CairnSurgical, Inc.
CairnSurgical is a clinical-stage medical device company in Lebanon, New Hampshire, building patient-specific surgical guidance for breast cancer lumpectomy. Its Breast Cancer Locator (BCL) System pairs a 3D-printed, bra-like form molded to each patient's anatomy with an interactive 3D Visualizer derived from supine MRI, giving surgeons a precise blueprint of a tumor's size, shape, depth and edges. The goal is to cut the 20 to 25 percent re-excision rate in breast-conserving surgery toward zero. Spun out of Dartmouth College and Dartmouth-Hitchcock Medical Center in 2015, the company reported 94 percent margin-negative resections in a European study and filed for FDA De Novo clearance in 2026.
CREATE Medicines
CREATE Medicines is a Cambridge, Massachusetts clinical-stage biotech building in vivo immune programming - therapies that use an mRNA-lipid nanoparticle platform to turn a patient's own T cells, NK cells, and myeloid cells into chimeric antigen receptor (CAR) cells directly inside the body, rather than extracting and re-engineering them in a lab. Formerly Myeloid Therapeutics, the company rebranded in October 2025 as its pipeline expanded beyond myeloid cells and cancer into autoimmune disease and fibrosis. Its repeat-dosable, off-the-shelf approach aims to make CAR therapy cheaper and more scalable than conventional cell therapy, and the company says it has dosed more than 50 patients - among the largest clinical datasets for in vivo CAR to date.
HERVolution Therapeutics
HERVolution Therapeutics is a Copenhagen-based biotechnology company developing immunotherapies that target human endogenous retroviruses (HERVs) - dormant remnants of ancient viruses embedded in human DNA that can reactivate with age and disease. Formerly named InProTher, the company has engineered a proprietary platform that redesigns these 'dark genome' antigens to break immune tolerance, making them visible to the immune system for the first time. Its off-the-shelf vector-based pipeline, led by IPT-001, aims to treat cancer, metabolic disease, and other diseases of aging.
HiRO - Harvest Integrated Research Organization
HiRO (Harvest Integrated Research Organization) is a full-service, globally oriented clinical research organization founded in 2020 that helps biotech companies run clinical trials across borders. Positioning itself as an 'integrated' rather than a traditional 'contract' research organization, HiRO connects Asian biotechs seeking trials outside their region with US and European sponsors wanting to run studies in Asia. Backed by a tens-of-millions-of-dollars Series A led by OrbiMed and built out through three CRO acquisitions, it offers end-to-end services from preclinical strategy to regulatory submission, with deep expertise in oncology and rare disease.
Indi Molecular
Indi Molecular is a Culver City, California biotech developing a synthetic alternative to antibodies called Protein Catalyzed Capture (PCC) agents - small, stable cyclic peptides built with click chemistry that bind protein targets with antibody-like specificity while behaving like small-molecule drugs. Spun out of Caltech chemist James Heath's lab in 2013, the company applies its platform to targeted oncology therapeutics and PET imaging agents, aiming to reach targets long considered undruggable, including KRAS G12D pancreatic cancer and ovarian cancer.
K36 Therapeutics, Inc.
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.
NextRNA Therapeutics
NextRNA Therapeutics was a Boston-based biotechnology company pioneering small-molecule drugs that target long non-coding RNAs (lncRNAs) - a vast, largely undrugged region of the genome that regulates gene expression. Built on the science of Dana-Farber's Carl Novina and led by co-founder and CEO Dominique Verhelle, the company developed a proprietary discovery engine to map disease-relevant lncRNA-protein interactions and drug them with selective small molecules across oncology and immunology. NextRNA raised roughly $56 million in seed and Series A financing and signed a collaboration with Bayer worth up to $547 million before winding down operations in August 2025 amid a difficult biotech market and a missed partnership milestone.
Pathos AI
Pathos AI is an AI-driven biotech company building what it describes as one of the largest multimodal foundation models in oncology. By combining millions of clinical, molecular, and imaging records with proprietary AI, Pathos aims to identify the right patients for a given therapy, design smarter adaptive clinical trials, and de-risk cancer drug development. Founded in 2020 by Eric Lefkofsky and Ryan Fukushima and led since 2025 by CEO Iker Huerga, the company raised a $365 million Series D that valued it at roughly $1.6 billion.
PIC Therapeutics
PIC Therapeutics is a Natick, Massachusetts biotechnology company developing small-molecule precision medicines that target cancer at the level of protein translation. Rather than chasing individual oncogenes one at a time, PIC modulates the Pre-Initiation Complex (PIC) and the translation factor eIF4E - a convergence point for many oncogenic signaling pathways - to selectively shut down the production of cancer-driving proteins while sparing healthy cells. Founded on the research of Harvard structural biologist Gerhard Wagner and led by CEO Katherine Bowdish, the company is advancing an allosteric eIF4E modulator toward first-in-human studies in drug-resistant metastatic breast cancer, backed by a $35M Series A led by OrbiMed.
Pinetree Therapeutics
Pinetree Therapeutics is a Cambridge, Massachusetts biotech founded in 2019 that develops antibody-based targeted protein degraders for cancer. Its AbReptor and TAER-TAB platforms use modular bispecific and multispecific antibodies to hijack the body's own lysosomal machinery and eliminate disease-driving membrane-bound and extracellular proteins - including drug-resistant receptor tyrosine kinases that conventional inhibitors cannot reach. Led by founder and CEO Ho-Juhn Song, Ph.D., the preclinical company has raised roughly $111M to date, struck a $500M+ EGFR-degrader option deal with AstraZeneca, and is advancing lead oncology programs toward Phase I.
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is a Baltimore-based, clinical-stage drug discovery company spun out of Johns Hopkins University. Its RapaGlue platform designs non-degrading, cell-permeable macrocyclic molecular glues that modulate hard-to-drug intracellular and transmembrane targets - drawing on a proprietary DNA-encoded library of more than 8 billion compounds and machine learning for target selection. The lead program, RAP-0001, is a selective ENT1 inhibitor advancing toward IND-enabling studies for the prevention of acute kidney injury in cardiac surgery patients, with a broader pipeline spanning oncology, immunology, and pain.
Ring Therapeutics
Ring Therapeutics is a Cambridge, Massachusetts biotechnology company founded by Flagship Pioneering to build a new class of gene therapy delivery vectors from anelloviruses - the most abundant and diverse family of viruses that naturally and harmlessly live inside the human body. Because these commensal viruses evade the immune system, Ring's AnelloVector platform aims to solve gene therapy's biggest limitations: the inability to re-dose patients, pre-existing immunity, and narrow tissue targeting. Through its Anellogy discovery platform and AnelloBricks in-vitro manufacturing technology, Ring is engineering re-dosable, tissue-specific, scalable vectors intended to carry a wide range of therapeutic payloads.
Sanavia Oncology Inc.
Sanavia Oncology is a New York-based biotech company developing next-generation cancer immunotherapies for patients who don't benefit from existing treatments. Its proprietary platform pairs high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence to discover novel, clinically relevant cancer-specific epitopes in drug-resistant tumors, then generates antibodies with atomic-level specificity to those targets. The company is building antibody drug conjugates (ADCs), bispecific T cell engagers (TCEs) and CAR-T therapies - led by its SANA-01 ADC - and is backed by Two Bear Capital.
Scorpion Therapeutics
Scorpion Therapeutics was a Boston-based, clinical-stage precision oncology company built to advance what it called "Precision Oncology 2.0" - pairing cancer biology, computational chemistry, medicinal chemistry and genomics to design small-molecule drugs against cancer targets that had resisted earlier approaches. Founded in 2020 by a group of prominent scientists and biotech operators, it raised more than $440 million and built a pipeline of mutant-selective inhibitors, most notably the PI3K-alpha inhibitor STX-478 and a franchise of fourth-generation EGFR inhibitors. In January 2025 Eli Lilly agreed to acquire the company and its PI3K-alpha program in a deal worth up to $2.5 billion, while Scorpion's remaining pipeline and staff were spun into a new independent company, Antares Therapeutics.
SEED Therapeutics
SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by proteins long considered undruggable. Powered by its proprietary RITE3 discovery platform - which pairs disease-causing target proteins with the most suitable of more than 600 human E3 ligases - SEED reprograms the cell's own ubiquitin-proteasome system to destroy harmful proteins rather than merely block them. Founded in 2020 by CEO Lan Huang and a group of protein-degradation pioneers including Nobel laureate Avram Hershko, the company advanced its lead oral RBM39 degrader ST-01156 into first-in-human Phase 1 trials in early 2026, with a broader pipeline spanning oncology, neurodegeneration, immunology and virology backed by partners Eli Lilly and Eisai.
Shorla Oncology
Shorla Oncology is a specialty pharmaceutical company based in Clonmel, Ireland, with a U.S. base in Cambridge, Massachusetts, that develops and commercializes innovative oncology drugs for orphan and pediatric cancers. Founded in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla focuses on indications where existing treatments are limited, in shortage, or poorly suited to patients - reformulating and reinventing cancer therapies into easier-to-administer forms such as oral liquids and ready-to-dilute vials. The company markets four FDA-approved products in the U.S. and is advancing an early-stage pipeline addressing rare cancers.
SpotitEarly
SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.
Stablix, Inc.
Stablix, Inc. is a preclinical biopharmaceutical company pioneering targeted protein stabilization (TPS), a new therapeutic modality that does the opposite of protein degraders. Its RESTORE platform generates heterobifunctional small molecules called RESTORACs that recruit deubiquitinase enzymes (DUBs) to selectively remove ubiquitin from disease-relevant proteins, restoring deficient proteins to therapeutic levels or correcting aberrant protein function. Co-located in New York City and Boston and founded on science from Columbia University, Stablix has raised roughly $78M and is developing programs in cancer, rare diseases and immunological disorders, including a strategic collaboration with Vertex Pharmaceuticals.